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A process to coat particles of active pharmaceutical ingredient (API) onto microcrystalline cellulose
(MCC) excipient shows promise as a new way to dosage forms showing enhanced drug release. The pro-
cess consists of a fluidized bed operated at elevated pressure in which API particles are precipitated from
a Supercritical Anti-Solvent process (SAS). MCC particles were used as an excipient in the fluidized bed
and collect the SAS-generated API particles. Naringin was selected as the model API to coat onto MCC.
A number of operational parameters of the process were investigated: fluidization velocity, coating pres-
sure, temperature, concentration of drug solution, drug solution flow rate, drug mass, organic solvent,
MCC mass and size and CO2-to-organic solution ratio. SEM and SPM analyses showed that the MCC par-
ticle surfaces were covered with near-spherical nanoparticles with a diameter of approximately 100–
200 nm, substantially smaller than the as-received API material. XRD showed that naringin changed from
crystalline to amorphous during processing. The coated particles resulting from the SAS fluidized bed
process have a higher loading of API, gave faster release rates and higher release ratios in comparison
with those produced using a conventional fluidized bed coating process. The approach could be trans-
ferred to other industries where release is important such as agrochemical, cosmetic and food.
 2016 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction approaches [1]. This is attributed to an enhanced dissolution rateActive pharmaceutical ingredients (API) in nanoparticulate
form have advantageous properties, such as higher dissolute rate
and greater bioavailability than those prepared by conventionaldue to the particle size and intrinsic solubility. Previous studies
on a number of poorly soluble drugs have demonstrated that par-
ticle size reduction resulted in an increase rate of dissolution and
higher oral bioavailability [2].
Nanosizing in the pharmaceutical industry refers to the reduc-
tion of the API particle size down to a sub-micron range [3]. Over
the past few decades, a range of processes including milling,
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pharmaceutical industry to reduce the particle size, in order to
achieve desired performance. However, nanoparticles are not read-
ily attainable through conventional routes and a subsequent com-
minuting stage is often necessary, which involves large amounts of
energy input and may alter the physicochemical properties of the
product [1,4].
To address the above mentioned technical challenges in gener-
ating sub-micron particles, it has been demonstrated that the
micronization using supercritical fluids routes [5,6], especially
the Supercritical Anti-Solvent (SAS) process, has great potential
[7–11]. The SAS process makes use of the high solvent power of
supercritical fluids to dissolve certain organic solvents and to act
as an anti-solvent to drugs that have no or low solubility in the
selected supercritical fluid, thereby causing their simultaneous
precipitation. In a typical SAS process, the API of choice is dissolved
in an organic solvent and is injected into the supercritical fluid
through a small diameter nozzle, which rapidly causes its supersat-
uration and precipitation as a result of the instantaneous miscibil-
ity of the supercritical fluid with the organic solvent. Due to the
high and uniform degree of supersaturation, small particles of
API with a narrow particle size distribution are obtained. The SAS
process has been proven to be effective in preparing nanoparticles
for many active drugs [11].
Several authors have combined supercritical fluids and fluidized
beds in the past to coat materials in a fluidized bed. Some research-
ers have reported a fluidized bed process operating at ambient
pressure to capture particles (not APIs) or wax from a supercritical
CO2 stream flowing into the bed [12,13], in a process similar to
RESS (Rapid Expansion of Supercritical Solutions). Others have
described the fluid dynamics of a fluidized bed operating at super-
critical conditions [14] and have subsequently operated the flu-
idized bed [15] and injected CO2 laden with wax to coat glass
beads. Rosenkranz et al. [16] have used a variation of the process
to precipitate a protein from aqueous solution onto a supercritical
CO2 fluidized bed of lactose, while simultaneously injecting a
supercritical mixture of CO2 and paraffin at high temperature
and pressure which encapsulates the BSA protein on the lactose.
A recent paper [17] describes a process to coat polymer film from
an ethanol solution onto titanium particles by precipitation from a
supercritical carbon dioxide fluidized bed. However, until the cur-
rent work there has been no experimental demonstration of the
use of SAS within a pressurized fluidized bed to coat API particles,
with proof of their release properties. The process captures the SAS
generated nanoparticles onto excipient carrier particles causing
build-up of a coating. The immediate collection of nanoparticles
in the process onto an excipient close to their point of origin, pre-
vents further particle growth and agglomeration, forming a pro-
duct which retains the efficacy and special features of the
nanometer size in an easily handleable form. The process combina-
tion could potentially offer an even greater opportunity to signifi-
cantly improve the coating properties, whilst retaining and taking
advantage of the nanoparticulate form of the API in drug release
applications. The approach could be transferred to other industries
where release is important such as agrochemical, cosmetic and
food.
Naringin (C27H32O14, CAS: 10236-47-2) is a double hydrogen fla-
vonoid compound and has antioxidant, anti-inflammatory, anti-
cancer, anti-allergic and anti-diabetic properties. The solubility of
naringin in water (20 C) is poor, which leads to low bioavailability
and hinders further studies on its pharmacological actions [18–20].
The work reported here uses naringin as a model drug in a
Supercritical Anti-Solvent Fluidized Bed process in order to
improve its dissolution properties. A number of parameters were
studied in order to optimize the process: the fluidization velocity,
coating pressure, temperature, concentration of drug solution, drugsolution flow rate, drug mass, organic solvent, MCC mass and size
and CO2-to-organic solution ratio. The drug release profiles of the
coated composite particles were determined.2. Experimental
2.1. Materials
All materials were used as purchased without further purifica-
tion: Naringin (99.0%) was donated by Professor Su Weiwei (Sun
Yat-sun University, PR China); Carbon dioxide (P99.8%) was pur-
chased from BOC UK; Microcrystalline cellulose: Ethispheres 150,
250 and 450, with particle size ranges of: 100–200, 200–355 and
355–500 lm, respectively, and particle density of 1.4 g/cm3 were
imported from NP Pharm, Bazainville, France. MethanolP 99.8%,
ethanolP 99.8% and acetoneP 99.8% were all bought from
Sigma-Aldrich Company Ltd. Dorset, UK.
2.2. Apparatus
The experiments were carried out in a SAS-fluidized bed
(SASFB) coating rig developed in-house. Fig. 1 shows a schematic
of the SAS fluidized bed coating equipment in which a former
SAS rig [7] was modified to accommodate a fluidized bed located
inside a high pressure vessel (HPV). Supercritical CO2 was intro-
duced from the bottom of the HPV which acted as an anti-
solvent, causing precipitation of the naringin from the selected
organic solvent solution. The CO2 also acted as fluidizing gas for
the MCC excipient particles within the vessel. The organic solvent
or organic solution containing naringin was injected by a HPLC
pump at the desired flow rate into the MCC fluidized bed where
the precipitating API particles produced by the SAS process were
coated onto the MCC. A 90 lm sintered plate gas distributor is
located at the base of the fluidized bed to ensure a uniform sc-
CO2 flow; a 127 lm ID stainless steel capillary is used as the nozzle,
through which the organic solution was injected into the CO2
stream and MCC bed.
The MCC was held in a conical glass tube fitted on the top of
brass plenum chamber (see Figs. 1 and 2) to form a fluidized bed
through which the sc-CO2/organic solvent (solution) passes; and
the coating process occurs. The diameter of the fluidized bed at
the base was 6.5 mm giving a cross sectional area of 33.18 mm2.
Due to the conical nature of the tube, the cross-sectional area of
the bed surface increased with the mass of MCC loaded. In the tests
typically 1 to 4 g MCC was used; for a bed mass of 1 g the associ-
ated bed diameter was 12.6 mm, for 2 g this was 14.2 mm and
for 4 g it was 18.4 mm.
A mesh filter with 44 lm openings was fitted on the top of the
glass tube to prevent MCC being blown out from the bed. The sc-
CO2/organic solvent phase was depressurized to c. 20 bar and
entered a middle pressure vessel (MPV), where the solvent was
separated and recovered. Solvent-free CO2 then passed through a
cyclone to remove any residual solid and liquid prior to venting.
2.3. SAS-fluidized bed coating procedure
MCC particles were charged into the glass tube of the fluidized
bed before the high pressure vessel was closed. Supercritical CO2
was introduced into the vessel from the top of the HPV (not shown
in Fig. 1) until the desired pressure was reached. Once the pressure
stabilized the CO2 inlet was switched from the top to the bottom of
the HPV, allowing it to pass through the MCC to create the fluidized
bed. Naringin was dissolved in organic solvent at the desired con-
centration. When the pressure, temperature and fluidized bed
were stable, the pure organic solvent was injected into the
recovered organic 
solvent
water in
water out
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(10 to 20 bar)
PT
CO2 cylinder
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HPLC pump
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Fig. 1. Schematic of the SAS-fluidized bed rig. Flow meter = Rheonik Rhe08, HPV = Baskerville, UK pressure vessel max working P 300 bar at 100 C; BPR = Tescom 26-1762-
24, Germany; HPLC =Waters M-6000, Waters Associates, USA.
Fig. 2. Image of the plenum with the base of the glass fluidized bed attached, left; and underside of plenum showing nozzle tube to inject organic solution of API, right.
Q. Li et al. / Chemical Engineering Journal 313 (2017) 317–327 319fluidized bed to purge and equalize the system pressure. The sol-
vent was then switched to the naringin solution to start the coating
process. After the desired coating time had passed, the solution
flow was reverted to the pure solvent to purge the pipe lines at
the same flow rate as the process while maintaining a constant
CO2 flow. After 10 mL purge solvent passed, the organic solvent
pump was stopped and CO2 was purged for a further 30 min to
wash the fluidized MCC particles, so removing any residual solvent.
The pressure was then reduced to atmospheric in stages. Once at
ambient, the Naringin-coated MCC particles were removed from
the fluidized bed for further characterization.
2.4. Optimization of SAS fluidized bed process
The fluidizing velocity, coating pressure, temperature, concen-
tration of drug solution, drug solution flow rate, drug mass, organic
solvent, MCC mass, CO2-to-organic solution ratio, and the MCC
diameter are considered the most important parameters for inves-
tigation in the SASFB process. The optimization of the operating
conditions for the coating process was carried out systematically.The procedure consisted of manipulating the nine variables
which are listed in Tables 1 and 2. The drug release ratio and the
loading of naringin on MCC were chosen as response variables to
compare the coating results. The nine variables and their ranges
(shown in parentheses) used in the experiments were coating pres-
sure (80, 120, 150 bar), coating temperature (35, 40, 50 C), narin-
gin solution concentration (2.5, 5.0, 10.0, 15.0 mg/mL), drug
solution flow rate (0.3, 0.5, 1.0, 1.5 mL/min), MCC mass (1.0, 2.0,
4.0 g, MCC particle average diameter (175, 295, 444 lm), (mea-
sured by Helos (H2290) & Rodos, Sympatec GmbH, Clausthal-
Zellerfeld, Germany), total drug mass used per test (25.0, 50.0,
75.0, 100.0 mg), carbon dioxide flow rate (12, 25, 40 g/min), and
solvent choice (ethanol, methanol, acetone). The ranges of each
variable were based on the results of preliminary experiments.
2.5. Conventional fluidized bed coating procedure
A conventional fluidized bed coating process (test 23) was used
to benchmark the SAS-fluidized bed performance. Twenty
grammes of MCC particles were coated with naringin using a
Table 1
The nine variables and ranges used in the experimental study.
P T Fdrug solution Cdrug Mdrug Solvent MMCC RCO2/solution DMCC
bar C mL/min mg/mL mg g g/mL lm
80–150 35–50 0.25–1.5 2.5–15 25–100 3 1–4 16.7–83.3 175–444
Table 2
Details of experimental parameters.
Exp. P T Fdrug Cdrug Mdrug Solvent MMCC FCO2 DMCC
No. bar C mL/min mg/mL mg g g/min lm
1 120 40 0.5 5 50 EtOH 2 25 295
2 80 40 0.5 5 50 EtOH 2 25 295
3 150 40 0.5 5 50 EtOH 2 25 295
4 120 35 0.5 5 50 EtOH 2 25 295
5 120 50 0.5 5 50 EtOH 2 25 295
6 120 40 0.3 5 50 EtOH 2 25 295
7 120 40 1 5 50 EtOH 2 25 295
8 120 40 1.5 5 50 EtOH 2 25 295
9 120 40 0.5 2.5 50 EtOH 2 25 295
10 120 40 0.5 10 50 EtOH 2 25 295
11 120 40 0.5 15 50 EtOH 2 25 295
12 120 40 0.5 5 25 EtOH 2 25 295
13 120 40 0.5 5 75 EtOH 2 25 295
14 120 40 0.5 5 100 EtOH 2 25 295
15 120 40 0.5 5 50 MeOH 2 25 295
16 120 40 0.5 5 50 Acetone 2 25 295
17 120 40 0.5 5 50 EtOH 1 25 295
18 120 40 0.5 5 50 EtOH 4 25 295
19 120 40 0.5 5 50 EtOH 2 12.5 295
20 120 40 0.5 5 50 EtOH 2 40 295
21 120 40 0.5 5 50 EtOH 2 25 444
22 120 40 0.5 5 50 EtOH 2 25 175
23a 0 50 0.5 5 500 EtOH 20 0 295
a Test 23: conventional fluidized bed coating process for comparison; EtOH = ethanol; MeOH = methanol.
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0.5 g talc was added to prevent static. The atomizing nozzle was
located at the centre of the lower plenum with a diameter of
0.5 mm. The coating solution was precisely introduced into the
nozzle using a syringe pump. The coating operating conditions
were close to ambient pressure, 50 C, compressed air flow rate
of 30 m3/h, atomizing air flow rate of 0.5 m3/h and coating solution
injection rate: 500 lL/min.
2.6. Particle characterization
2.6.1. Quantitative determination of drug loading
The loading of naringin on MCC (mg naringin/g MCC) was mea-
sured using a UV detector (UV-2075 plus, Jasco, Japan) by quanti-
tatively dissolving the coated sample in an appropriate solvent,
measuring the absorbance of the solution at the specific wave-
length (283 nm) and comparing the response with a standard
curve (R2 = 0.9999). The loading of the naringin on MCC was then
determined by back calculation.
2.6.2. SEM
Naringin coated MCC and unprocessed naringin samples were
deposited onto double sided tape and sputtered with platinum at
pressure of 0.5 mbar for 120 s. SEM images were taken using a Phi-
lips XL30 ESEM-FEG electron microscope [Philips, Netherlands] fit-
ted with an Oxford Inca 300 EDS system [Oxford Instruments, UK].
The imaging was performed at 5–10 kV and 10 mA.
2.6.3. SPM
A scanning probe microscope (SPM) (NanoWizard II, JPK, Cam-
bridge, UK) was used to acquire the topography of MCC, SASFB pro-
cess coated and traditional process coated MCC. The SPMmeasurements were carried out in an ambient environment in
intermittent contact mode, using cantilevers (MikroMasch, Ger-
many) with a spring constant of 7 N/m.
2.6.4. XRD analysis
Processed and unprocessed naringin XRD diffraction patterns
were collected by an XRD diffractometer (Philips, Xpert-pro, the
Netherlands) with a rotating anode and Cu Kak radiation gener-
ated at 30 mA and 40 kV over the 2h range from 5 to 80.
2.6.5. FT-IR analysis
Processed naringin and unprocessed naringin were mixed with
KBr at 1% naringin/KBr (w/w) separately and pressed to obtain self-
made discs which were then characterized by FTIR (IRAFFINITY,
Shimadzu Co.) Spectra were collected over 4000–600/cm
wavenumbers at a resolution of 4/cm.
2.6.6. In vitro dissolution studies
The tests used simulated gastric fluid (0.1 M hydrochloric acid
aqueous solution) as dissolution medium and were carried out in
200 mL of such fluid. The samples evaluated consisted of particles
from four different conditions as follows: SAS fluidized bed process
naringin coated MCC (designated as SAS-FB), a physical mixture of
unprocessed naringin with excipient of 1:1 lactose and MCC (des-
ignated as Mixture), conventional fluidized bed preparated narin-
gin coated MCC (designated as FB) and unprocessed naringin
(designated as API). The stirring temperature and speed were set
at 37 ± 0.5 C and 35 rpm, respectively. At the sampling time of 1,
3, 5, 10, 20, 30, 45 and 60 min, 3 mL aliquots were taken and
replaced by 3 mL dissolution medium. All solutions prepared for
analysis were filtered through a 0.22 lm nylon membrane before
analysis. The concentration of the naringin was determined by an
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USA). The absorbance of the standard and sample was measured
at the maximum absorption wavelength of naringin (283 nm).
The amount of naringin in the solution was calculated by a calibra-
tion curve (R2 = 0.9999), which was prepared by using standard
solutions in the appropriate concentration range. Each point was
the average of triplicate tests.
3. Results and discussion
3.1. Operation of the fluidized bed
As noted earlier, the bed used in this work was of very small
dimensions (base diameter 6.5 mm) and a truncated cone in shape,
compared with that used for studies of fluidization behavior by, for
example, Vogt et al. [14] (using cylindrical columns of 21 or 39 mm
diameter). The shape was chosen in order to enhance the circula-
tion of the excipient particles, which is usual in fluidized bed coat-
ing processes in order to ensure uniform coating and prevent
agglomeration. Both the scale and shape of the bed, and its opera-
tion within a pressure vessel, prevented accurate measurement of
minimum fluidization velocity under operating conditions. It was
possible, however, to determine by visual observation the mini-
mum operating velocity necessary for particle circulation, UC;
results are presented in Fig. 3; UC is here based on the total fluid
flow through the bed and is referenced to the cross section at the
base. The values are comparable with minimum fluidization veloc-
ities measured and calculated for group B particles by Vogt et al. It
is observed that the minimum circulation velocity increases with
bed mass, which is partially attributed to the shape of the bed.
It is of note here that although all three size cuts of the excipient
particles were within the range normally associated with Geldart’s
‘‘group B” (exhibiting no expansion before bubbling, at ambient
conditions) some apparently homogeneous expansion was
observed for all sizes as the gas velocity was increased. This is in
agreement with the observations of Vogt et al.
The coating experiments were conducted at gas velocities
between 1 and 3.8UC, with the majority being undertaken at
1.9UC (this relates to the standard condition of 120 bar, 40 C,
25 g/min CO2 and 2 g MCC). In all cases, homogeneous expansion
had given way to bubbling at this velocity.
3.2. SEM morphology of SAS-fluidized bed coating particles
The morphology of the nanoparticles on the surface of the MCC
was evaluated using SEM. Micrographs of a typically coated MCCFig. 3. Minimum circulation velocity, Uc over a range of pressures at 40 C. Velocity
based on base cross-section.particles made by test 14 in Table 2 and an uncoated reference
MCC particle treated by the SAS fluidized bed process at the same
conditions as the coated sample, but without naringin added to the
system, are shown in Fig. 4. For comparison, unprocessed API and
conventional fluidized bed coated MCC prepared by test 23 (see
Table 2) are also shown in Fig. 4.
Uncoated MCC (particle size: 295 lm) in Fig. 4(a) exhibits a
nearly spherical, smooth surface. The coated MCC in Fig. 4(b)–(d)
produced using SASFB show the typical morphology of the naringin
particles on the coated surface at different magnifications. High
magnification imaging (Fig. 4(e)) shows that the coating consists
of particles between 100 and 200 nm, which are reduced from their
original size (which had dimensions of 14  10  2 lm) as shown
in Fig. 4(f). The small particle size can be attributed to the way
the particles were produced by the SAS process. When the organic
solution containing naringin enters the fluidized bed, the solvent is
immediately mixed with the sc-CO2, causing rapid formation of
naringin nuclei which contact and adhere on the MCC surface,
restricting further growth. Fig. 4(c)–(e) also show that several lay-
ers of the 100–200 nm nanoparticles are formed and appear to
have platelet-type morphology (Fig. 4(e)). Conversely, in the con-
ventional fluidized bed, when the solution enters the fluidized
bed, the solution wets the excipient surface and the solvent is then
evaporated by the hot fluidizing air. A continuous layer of naringin
without discrete particles is formed over the MCC surface, as
shown in Fig. 4(g) and (h).
3.3. SPM of particles on MCC
In addition to SEM, SPM was used to confirm the coating of MCC
(295 lm) with naringin nanoparticles (100 nm). During SPM
measurement, a sharp cantilever with tip radius of 10 nm was
employed to scan the sample surface. MCC samples treated under
different processes were analysed. The results of SPM are shown in
Fig. 5, in which Fig. 5(a) shows the surface of the uncoated MCC
spheres. It was found that the MCC surface is composed of agglom-
erates of the cellulose matrix of around 7 lm. Fig. 5(b) shows the
Naringin-covered morphology of the MCC surface prepared by
the conventional fluidized bed approach of test 23 in Table 2,
which results in flake-like objects of micron size; this is consistent
with the results shown in Fig. 4(g) and (h). Fig. 5(c) shows
Naringin-coated MCC prepared by the SAS fluidized bed process
of test 7 in Table 2. It confirms that the MCC surface was covered
with spherical structures with a diameter of approximately
100 nm.
3.4. Characterization of nanosized naringin
Samples of processed and unprocessed naringin underwent FT-
IR and XRD analyses to ascertain any change to chemical structure
during processing. The FT-IR results are shown in Fig. 6, where the
blue line labelled ‘‘Naringin SAS” is SAS fluidized bed processed
material, while the red line labelled ‘‘Naringin API” is unprocessed
(as-received) naringin. The scan results show no significant differ-
ence. The results of the XRD are shown in Fig. 7 with the same
notation for the samples as in Fig. 6. It can be seen that processed
naringin lost all characteristic peaks, changing from crystalline to
amorphous during processing as the precipitation process is too
fast for the crystal structure to order itself.
3.5. Dissolution profiles of processed and unprocessed naringin
Fig. 8 shows the release rate curves of naringin from SAS flu-
idized bed particles (SAS-FB) made by test 10 in Table 2, API as-
received (API), a physical mixture of the excipient (1:1 lactose
and MCC) and API (i.e. uncoated) at the same naringin content as
(a) (b) 
(c) (d) 
(e) (f) 
(g) (h)
Fig. 4. SEM images of uncoated MCC, naringin coated MCC, and original naringin. Assays: (a): uncoated reference MCC (295 lm, processed with ethanol). (b): naringin coated
MCC (made by test 14 in Table 2; 5 mg/mL) at magnification 1000; (c): at 5000; (d): at 20,000 and (e): at 70,000. (f): untreated naringin API. (g): conventional fluidized
coating MCC (made by test 23 in Table 2) at magnification 1000 and (h): at 20,000.
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Fig. 5. Coating results by SPM. Assays: (a) Uncoated MCC (295 lm) surface. (b) Surface of naringin coated MCC obtained from conventional fluidized bed coating, test 23 in
Table 2; 5 mg/mL. (c) Surface of naringin coated MCC obtained from SASFBC coating test 7 in Table 2; 5 mg/mL.
Q. Li et al. / Chemical Engineering Journal 313 (2017) 317–327 323the loading of SAS fluidized bed particles (Mixture) and conven-
tional fluidized bed particles (FB) made by test 23 in Table 2.
Fig. 8(a) and (b) show that the release rate of naringin coated on
MCC by the SAS fluidized bed process is faster than all three other
approaches and has the highest release ratio. The nanoparticles
released 90% of the API in the first minute and become stabilized
at c. 100% in 3 min, while the as-received API and the API + excipi-
ent mixture give release less than 45% in the first minute and had
not completely stabilized at 60 min. The conventional fluidized bed
particles (FB) give 80% release in the first minute and become sta-
bilized at c. 90% in 3 min. The results show that the naringin
nanoparticles on the MCC produced by the SAS fluidized bed pro-
cess lead to almost immediate naringin release.
3.6. The effect of SAS fluidized bed process parameters on naringin
dissolution profiles
The particle size obtained by the SAS process is affected by the
process parameters. During a SAS fluidized bed process, the MCC
excipient in the fluidized bed captures a substantial proportion of
the nuclei, so restricting their further growth. In tests without
the fluidized bed the SAS process alone gave agglomerated parti-
cles that were ‘‘fluffy” in nature, with a very low bulk density
and sizes of approximately 1–2 mm wide and 5 mm in length; this
demonstrates the clear advantage of the SAS fluidized bed process
at restricting particle agglomeration.
The enhanced release rate of naringin is a significant outcome of
the SAS fluidized bed process due to the particle size, morphology,
loading and degree of aggregation of API on the MCC excipient. Nodirect comparison of the SAS fluidized bed process parameters on
drug release can be made with the literature as this is the first time
this process has been reported; however the results in Fig. 9 can be
used for future work and process design. It can be seen that there is
a high immediate release rate for all samples over the range of pro-
cess conditions. It is evident, however, that the release profiles cor-
relate with the process parameters. Fig. 9a shows the effects of
process pressure on drug release. It is clear that there is an opti-
mum process pressure; with all other parameters constant, as
the pressure increases (tests 1, 2 and 3 in Table 2), the final release
of naringin increases to its maximum at 120 bar then decreases.
Fig. 9b shows release rates of samples made by tests 1, 4 and 5
in Table 2 operated at three temperatures and the data show that
a process temperature between 40 and 50 C results in a product
with faster release than that produced at 35 C. Fig. 9c shows that
the naringin solution flow rate within the test range (tests 1, 6, 7
and 8) has almost no effect on the release rate.
Fig. 9d shows that for the range of drug concentrations (tests 1,
9, 10 and 11) release ratios >95% were achieved with 10 mg/ml giv-
ing a 5% higher value. The drug concentration generally has a small
effect on the release rate. It was observed that a deeper fluffier
coating layer resulted when lower concentrations of naringin solu-
tion were used. Due to the porous structure, water molecules can
be easily transported through the shell, resulting in an accelerated
dissolution. The dissolution rate therefore increases as the naringin
concentration increases, from 2.5 to 10 mg/mL. When the naringin
concentration was increased to 15 mg/mL, closer packing and
agglomeration of particles is observed; this can be seen by compar-
ing the images in Fig. 10. Due to the agglomeration, and the closer
Fig. 7. XRD patterns of naringin API (below) and SASFBC processed naringin (top).
Fig. 8. The effect of different methods on dissolution rate. (a) SAS fluidized bed particles (SAS-FB), physical mixture particles (Mixture), API particles (API) and conventional
fluidized coating particles (FB) release curves in 60 min; (b) SAS fluidized bed particles, physical mixture particles, API particles and conventional fluidized coating particles
release 0–10 min release curves;
Fig. 6. FT-IR spectra of naringin API (red) and SASFBC processed naringin (blue). (For interpretation of the references to colour in this figure legend, the reader is referred to
the web version of this article.)
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and the overall dissolution rate decreases. Lower relative concen-
trations are therefore beneficial to API release.
Fig. 9e shows that when the total drug used is between 2.5 and
5 wt% of the excipient mass (tests 1, 12 and 13), the coating shows
better properties than when a lower feed 1.25 wt% of excipient
mass (test 14) is used.
The API solubility depends on the particular organic solvent.
The solubility of naringin has been given by Zhang et al. [21] as
24.4 mg/mL (20 C) and 28.6 mg/mL (25 C) in methanol. Further-
more, Naringin can completely dissolve in ethanol, methanol and
acetone at the maximum concentration of 15 mg/mL used in the
experiments. Higher concentrations of naringin, between 20 and30 mg/mL, were observed to dissolve. The polarisation differences
between ethanol, methanol and acetone lead to different solubili-
ties in supercritical carbon dioxide, and will influence the SAS pro-
cess and the subsequent dissolution and release rates. Fig. 9f (tests
1, 15 and 16) shows indirectly the effect of solvent choice (and
indirectly the solubility) on the coating results. Ethanol, acetone
and methanol are all suitable for the coating process with all three
solvents producing similar particles; however as seen in Fig. 9f ace-
tone gave the highest release rate.
The geometric shape of fluidized bed was fixed, and therefore,
the height of fluidized bed is dependent on the mass of MCC used.
Fig. 9g shows that MCCmasses of 1–4 g (tests 1, 17 and 18) all gave
acceptable coating results (as indicated by the release rate)
Fig. 9. The effect of different process parameter on release rate. Read in conjunction with Table 2. (a) Effect of coating pressure; samples prepared from tests 1, 2 and 3. (b)
Effect of coating temperature; samples prepared from tests 1, 4 and 5. (c) Effect of drug solution flow rate; samples prepared from tests 1, 6, 7 and 8. (d) Effect of drug
concentration; samples prepared from tests 1, 9, 10 and 11. (e) Effect of drug mass; samples prepared from tests 1, 12, 13 and 14. (f) Effect of solvents; samples prepared from
tests 1, 15 and 16. (g) Effect of MCC mass in fluidized bed; samples prepared from tests 1, 17 and 18. (h) Effect of CO2 flow rate; samples prepared from tests 1, 19 and 20. (i)
Effect of MCC diameter samples prepared from tests 1, 21 and 22.
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Fig. 10. Micrographs of naringin particles on the surface of MCC at 15 mg/ml (left) and 5 mg/mL (right).
Table 3
Experimental parameters and coating results.
Exp P T Drug solution flow Cdrug Drug total mass fed Solvent MCC mass CO2 flow rate DMCC Drug content Coating efficiency
No. bar C mL/min mg/mL mg g g/min lm w/w% w/w%
1 120 40 0.5 5 50 EtOH 2 25 295 2.4 96.9
2 80 40 0.5 5 50 EtOH 2 25 295 2.3 90.0
3 150 40 0.5 5 50 EtOH 2 25 295 2.0 81.4
4 120 35 0.5 5 50 EtOH 2 25 295 2.1 85.1
5 120 50 0.5 5 50 EtOH 2 25 295 2.4 96.5
6 120 40 0.3 5 50 EtOH 2 25 295 1.9 75.3
7 120 40 1 5 50 EtOH 2 25 295 2.5 99.2
8 120 40 1.5 5 50 EtOH 2 25 295 2.1 85.5
9 120 40 0.5 2.5 50 EtOH 2 25 295 2.5 99.8
10 120 40 0.5 10 50 EtOH 2 25 295 1.6 62.6
11 120 40 0.5 15 50 EtOH 2 25 295 1.7 66.5
12 120 40 0.5 5 25 EtOH 2 25 295 1.1 89.1
13 120 40 0.5 5 75 EtOH 2 25 295 2.9 77.4
14 120 40 0.5 5 100 EtOH 2 25 295 4.1 81.5
15 120 40 0.5 5 50 MeOH 2 25 295 2.0 77.9
16 120 40 0.5 5 50 Acetone 2 25 295 2.1 82.2
17 120 40 0.5 5 50 EtOH 1 25 295 4.1 82.3
18 120 40 0.5 5 50 EtOH 4 25 295 1.2 91.9
19 120 40 0.5 5 50 EtOH 2 12.5 295 1.1 44.6
20 120 40 0.5 5 50 EtOH 2 40 295 2.0 79.4
21 120 40 0.5 5 50 EtOH 2 25 444 2.2 88.1
22 120 40 0.5 5 50 EtOH 2 25 175 1.1 44.4
23a 0 50 0.5 5 500 EtOH 20 0 295 1.6 65.8
a 23: Conventional fluidized coating.
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release and 5% lower release ratio than the 2 and 4 g beds.
The gas flow rate is a key parameter in fluidizing the bed and
hence the efficacy of the process. Its effect on the product proper-
ties resulting in active release (tests 1, 19 and 20) are shown in
Fig. 9h. A CO2 flow above 12.5 g/min (1.1 UC) leads to a product
with an acceptable release rate and release ratio as the gas flow
rate is sufficient to keep the bed fluidized and circulating the
MCC. In this work the higher CO2 flow rate gave better release
rates. The release rates of samples from tests 1, 21 and 22 using
three different sizes of MCC are shown in Fig. 9i. The effect of
MCC diameter in the coating process on the product release rate
shows a tendency for the smaller size of MCC particles to have a
faster release rate. The release rates of large diameter MCC parti-
cles is relatively low, probably due to its lower specific surface
area.
3.7. The effect on drug content and coating ratio
Although the product release rate is the ultimate indicator for
judging the success of the process in this work, the drug content
(ratio of drug mass to MCC mass) and coating efficiency (ratio of
drug coated on MCC to total feed) are other key indicators. Thecoating efficiency was influenced by the MCC particle size with
the smaller 175 lm particle leading to low efficiencies as a result
of the smaller surface area available per particle. Poorly adhered
naringin would have been carried out in the CO2 stream during
the CO2 ‘‘wash” step at the end of the process as evidenced by
the collection of particles on the filter downstream of the bed.
Table 3 lists the drug content and coating efficiency of all tests.
It is convenient to see the effect of operational parameters on coat-
ing results and this table complements the data shown in Fig. 9.
Table 3 shows the drug content and coating efficiency of the
SAS-fluidized bed process to coat naringin on MCC. The drug load-
ings are between 1.1 and 4.1 w/w% and the coating efficiency can
reach 99.8% (test 9) when all the parameters are optimized. Over
the entire operational range, half the tests gave coating efficiencies
of more than 85%. In comparison, the conventional fluidized bed
coating method gave loadings of 1.6% and a coating efficiency of
65.8% at the conditions studied, which are less than the SAS-
fluidized bed process.
4. Conclusion
High release rates of a drug compound with low water solubil-
ity can be obtained using the supercritical anti-solvent fluidized
Q. Li et al. / Chemical Engineering Journal 313 (2017) 317–327 327bed process developed in this work. The new process gave better
results than a conventional fluidized bed coating process using
the same starting materials. The process results in a product con-
sisting of excipient carrier particles coated in nano-sized drug par-
ticles. SEM study showed that the nanoparticles of naringin have a
typical spherical morphology with particle sizes between 100 and
200 nm. SPM also confirmed that the surface was covered with
spherical structures with a diameter of approximately 100 nm.
XRD showed that naringin changes from crystalline to amorphous
during processing.
The work demonstrates the advantages of the combined flu-
idized bed and supercritical anti-solvent process and offers a new
alternative approach to production of a product form with favor-
able drug release profile. The dissolution tests demonstrated that
there are significant differences between the products of SAS-
fluidized bed process and coated particles produced by conven-
tional routes. The results showed that the naringin nanoparticle
coatings result in products which show immediate release, with
a cumulative dissolution of 90% in the first minute and 100% in
3 min. Thus, the SAS-fluidized bed process substantially increased
both the cumulative dissolution and dissolution rates of naringin.
Since the drug content of Naringin-coated MCC prepared by the
SAS-fluidized bed is around 2.5 wt%, it could be directly adminis-
tered orally, if desired. Downstream processes such as granulation
and tableting, which carry risks of causing nanoparticle agglomer-
ation or further changes in the crystal form might therefore be
unnecessary.
Datasets
Data underlying this study can be accessed through the Cran-
field University repository at 10.17862/cranfield.rd.4480199.
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